Colorectal Cancer

New contracts boost Lonza

New contracts boost Lonza

Lonza has signed two new agreements for the supply of monoclonal
antibody-based drugs that provide an early fillip for its contract
manufacturing business, which was adversely affected by
overcapacity in 2003.

Biotech blasts back in 2003

Biotech blasts back in 2003

2003 was the second best year of all time for the biotechnology
industry, and 2004 looks set to be even better. This is the verdict
of James Burrill, head of US merchant bank Burrill & Co, who
describes the industry as "rising...


Follow us


View more


Featured Suppliers